CN112293576B - Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper - Google Patents
Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper Download PDFInfo
- Publication number
- CN112293576B CN112293576B CN202011192544.4A CN202011192544A CN112293576B CN 112293576 B CN112293576 B CN 112293576B CN 202011192544 A CN202011192544 A CN 202011192544A CN 112293576 B CN112293576 B CN 112293576B
- Authority
- CN
- China
- Prior art keywords
- chlorogenic acid
- canine
- preparation
- medicine
- canine distemper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 title claims abstract description 60
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 title claims abstract description 60
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 title claims abstract description 60
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 title claims abstract description 60
- 229940074393 chlorogenic acid Drugs 0.000 title claims abstract description 60
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 title claims abstract description 60
- 235000001368 chlorogenic acid Nutrition 0.000 title claims abstract description 60
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 201000010099 disease Diseases 0.000 title claims abstract description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 44
- 241000701931 Canine parvovirus Species 0.000 title claims abstract description 40
- 208000000655 Distemper Diseases 0.000 title claims abstract description 37
- 208000014058 canine distemper Diseases 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims description 37
- 229940079593 drug Drugs 0.000 title abstract description 15
- 239000003674 animal food additive Substances 0.000 title abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 241000125945 Protoparvovirus Species 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims 1
- 230000036760 body temperature Effects 0.000 abstract description 17
- 230000036528 appetite Effects 0.000 abstract description 15
- 235000019789 appetite Nutrition 0.000 abstract description 15
- 230000002550 fecal effect Effects 0.000 abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 239000000284 extract Substances 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000001914 filtration Methods 0.000 description 27
- 241000282472 Canis lupus familiaris Species 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000205585 Aquilegia canadensis Species 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 241000208689 Eucommia ulmoides Species 0.000 description 13
- 239000000463 material Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 241000282465 Canis Species 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000628997 Flos Species 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000712083 Canine morbillivirus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 201000003102 mental depression Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000701925 Feline parvovirus Species 0.000 description 2
- 241000702625 Mink enteritis virus Species 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 241000121250 Parvovirinae Species 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000035611 feeding Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010015915 eye discharge Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of chlorogenic acid in preparing a medicine or a feed additive for preventing and/or treating canine parvovirus disease and canine distemper. Experimental results show that after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of puppies suffering from canine parvovirus disease are obviously improved, the cure rate of the medicine for canine parvovirus disease is 67%, the effective rate is 33%, and the total effective rate is 100%; after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of a sick canine distemper are all obviously improved, the cure rate of the medicine for treating canine distemper is 58%, the effective rate is 25%, and the total effective rate is 83%. Chlorogenic acid as the only active ingredient has good application prospect in preparing medicines or feed additives for preventing and/or treating parvoviral diseases and canine distemper.
Description
Technical Field
The invention belongs to the field of pharmacy, and in particular relates to application of chlorogenic acid serving as a unique active ingredient in preparing medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper.
Background
With the vigorous development of the pet industry, the number of dogs keeping is always increasing. In recent years, canine parvovirus disease and canine distemper have caused tremendous injury to the canine industry and canine breeders. The high morbidity and mortality makes canine parvovirus disease and canine distemper terrible diseases that are threatening to the health of canines.
Canine parvovirus (Canine Parvovirus, CPV) belongs to the Parvoviridae family (Parvoviridae), the Parvovirinae subfamily (Parvovirinae), the genus Protoparvovirus (Protoparvovirus), which also includes other viruses such as Feline Parvovirus (FPV), mink Enteritis Virus (MEV), and the like. Canine parvovirus disease (Canine Parvovirus Infection, CP) is a virulent infectious disease caused by canine parvovirus, and is the most dangerous to puppies of 2-6 months of age, with vomiting, diarrhea and hemorrhagic enteritis being the main clinical manifestations.
Canine Distemper (CD) is a highly contagious disease caused by Canine Distemper virus (Canine Distemper Virus, CDV), and has strong infectivity and mortality rate of more than 80%. The temperature of dogs in the initial stage of canine distemper symptoms is up to 39.5-41 ℃, and the dogs have inappetence, mental depression, watery secretion from eyes and noses, sneeze and diarrhea. The body temperature rise and cough with purulent nasal discharge and purulent eye discharge occur again within 2-14 days later, and meanwhile, gastrointestinal diseases, vomiting and diarrhea and poor appetite are caused. High mental depression and sleepiness. Typical neurological symptoms, oral leukoplakia, convulsions and mortality rate of up to 80% occur in the later stage of canine distemper.
At present, no particularly effective medicine is used for preventing and treating canine parvovirus diseases and canine distemper, and immunization is mainly considered, so that inactivated vaccines and attenuated vaccines with lower production cost are generally used. The main anti-canine parvovirus vaccine used in China is CPV-2b type, but the vaccine has proved that the vaccine cannot play a role in complete immunity to puppies; the vaccine for resisting the canine distemper virus is CDV-11 strain or combined vaccine, can only play a certain role in preventing the canine distemper, and cannot be used for treating the diseases.
Therefore, there is a great need to develop drugs capable of effectively treating canine parvovirus disease and canine distemper. At present, no report of using chlorogenic acid as the only active ingredient for preparing medicines for preventing and/or treating canine parvovirus diseases and canine distemper is seen.
Disclosure of Invention
The invention aims to provide the use of chlorogenic acid as the only active ingredient in preparing medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper.
The invention provides the use of chlorogenic acid as the sole active ingredient in the preparation of a medicament or feed additive for preventing and/or treating parvoviral diseases and/or pestilence diseases.
The invention also provides application of the traditional Chinese medicine extract in preparing a medicine or feed additive for preventing and/or treating parvoviral diseases and/or pestilence diseases, wherein the content of chlorogenic acid in the traditional Chinese medicine extract is 20.00-100.00 wt.%.
Further, the content of chlorogenic acid in the traditional Chinese medicine extract is 21.36wt.% to 98.00wt.%.
Further, the traditional Chinese medicine extract is an eucommia ulmoides leaf extract or a honeysuckle extract.
Further, the preparation method of the eucommia ulmoides leaf extract or the honeysuckle extract comprises the following steps of: decocting folium Eucommiae or flos Lonicerae in water, filtering, concentrating, and drying.
Further, the mass ratio of the eucommia ulmoides leaves or the honeysuckle to the water is 1:10 to 1:15; the decoction time is 0.5-1.0 hour, and the times of decoction are 2-3 times.
Further, the concentrating step further comprises a purifying step, wherein the purifying method is one or more selected from precipitation, extraction, adsorption and desorption of a chromatographic column and crystallization;
preferably, the purification method comprises the steps of sequential precipitation, extraction and crystallization, or sequential precipitation, adsorption and desorption of a chromatographic column and crystallization.
Further, the reagent adopted by the precipitation is ethanol, the reagent adopted by the extraction is ethyl acetate, the reagent adopted by the crystallization is ethyl acetate, and the macroporous adsorption resin adopted by the chromatographic column is HPD-100 or D-101.
Further, the parvoviral disease is canine parvoviral disease or chicken parvoviral disease, preferably canine parvoviral disease;
or, the pestilence is canine distemper.
Further, the medicine or feed additive contains 10mg-100mg chlorogenic acid in each unit preparation;
and/or the medicine or feed additive is an injection or a solid preparation.
Experimental results show that after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of puppies suffering from canine parvovirus disease are obviously improved, the cure rate of the medicine for canine parvovirus disease is 67%, the effective rate is 33%, and the total effective rate is 100%; after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of a sick canine distemper are all obviously improved, the cure rate of the medicine for treating canine distemper is 58%, the effective rate is 25%, and the total effective rate is 83%. The chlorogenic acid has very outstanding effect of treating canine parvovirus disease and canine distemper, can treat canine parvovirus disease and canine distemper by single use, and has high effective rate. Chlorogenic acid as the only active ingredient has good application prospect in preparing medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Detailed Description
The raw materials and equipment used in the invention are all known products and are obtained by purchasing commercial products.
Example one preparation of eucommia ulmoides leaf extract of the present invention
Medicinal materials: eucommia ulmoides leaf with chlorogenic acid content of 3.58wt.%.
The preparation method comprises the following steps: decocting folium Eucommiae in 10 times of water twice for 0.5 hr, filtering, mixing filtrates, concentrating to 1/10 of the volume of the stock solution, stirring, adding 5 times of ethanol, standing, filtering, concentrating the filtrate, recovering ethanol, and spray drying to obtain folium Eucommiae extract with chlorogenic acid content of 21.36-26.75wt.%.
Example II preparation of eucommia ulmoides leaf extract of the invention
Medicinal materials: eucommia ulmoides leaf with chlorogenic acid content of 3.58wt.%.
The preparation method comprises the following steps: decocting eucommia ulmoides leaves twice with 10 times of water for 0.5 hour each time, filtering decoction, combining filtrate, concentrating to 1/10 of the volume of original liquid, stirring, adding 5 times of ethanol, standing, filtering, concentrating filtrate under reduced pressure to recover ethanol and concentrating to the relative density of 1.05-1.15 (25 ℃), adding 15 times of ethyl acetate of concentrated liquid for extraction for 5 times, retaining ethyl acetate phase, concentrating, volatilizing at low temperature to obtain eucommia ulmoides leaf extract, wherein chlorogenic acid content is 55.81-63.47 wt%.
Example III preparation of eucommia ulmoides leaf extract of the invention
Medicinal materials: eucommia ulmoides leaf with chlorogenic acid content of 3.58wt.%.
The preparation method comprises the following steps: decocting folium Eucommiae in 10 times of water twice for 0.5 hr each time, filtering, mixing filtrates, concentrating to 1/10 of the volume of the original solution, stirring, adding 5 times of ethanol, standing, filtering, concentrating the filtrate under reduced pressure to recover ethanol and concentrate to relative density of 1.05-1.15 (25deg.C), extracting with 15 times of ethyl acetate for 5 times, retaining ethyl acetate phase, concentrating, standing at 0-10deg.C for 12 hr for crystallization, filtering, and drying at low temperature to obtain folium Eucommiae extract with chlorogenic acid content of 80.24-86.09 wt.%.
Example IV preparation of eucommia ulmoides leaf extract of the invention four
Medicinal materials: eucommia ulmoides leaf with chlorogenic acid content of 3.58wt.%.
The preparation method comprises the following steps: decocting folium Eucommiae with 10 times of water twice for 0.5 hr each time, filtering, mixing filtrates, concentrating to 1/10 of the volume of the stock solution, stirring, adding 5 times of ethanol, standing, filtering, concentrating the filtrate under reduced pressure to recover ethanol and concentrate to relative density of 1.05-1.15 (25deg.C), extracting with 15 times of ethyl acetate for 5 times, retaining ethyl acetate phase, concentrating, standing at 0-10deg.C for 12 hr for crystallization, filtering, saturated dissolving the crystals with ethyl acetate at 70deg.C, standing at 0-10deg.C for 12 hr for recrystallization, filtering, and drying at low temperature to obtain folium Eucommiae extract with chlorogenic acid content of more than or equal to 98wt%.
Example five preparation of honeysuckle extract of the invention
Medicinal materials: honeysuckle flower, chlorogenic acid content is 2.88%.
The preparation method comprises the following steps: decocting flos Lonicerae in 15 times of water for three times (each for 0.5 hr), filtering, mixing filtrates, concentrating to 1/10 of the volume of the original solution, stirring, adding 8 times of ethanol, standing, filtering, concentrating the filtrate to recover ethanol, and spray drying to obtain flos Lonicerae extract, wherein chlorogenic acid content is 15.78-20.52 wt.%.
Example six preparation of honeysuckle extract of the invention
Medicinal materials: honeysuckle flower, chlorogenic acid content is 2.88%.
The preparation method comprises the following steps: decocting honeysuckle in 15 times of water for three times, each time for 0.5 hour, filtering decoction, combining filtrate, concentrating to 1/10 of the volume of original solution, stirring, adding 8 times of ethanol, standing, filtering, concentrating filtrate, recovering ethanol, adsorbing by using HPL-100 macroporous adsorption resin chromatographic column, eluting with 60% ethanol, collecting eluent, concentrating, recovering ethanol, and spray-drying to obtain the honeysuckle extract, wherein chlorogenic acid content is 43.21-48.77 wt%.
Example seven preparation of honeysuckle extract of the invention
Medicinal materials: honeysuckle flower, chlorogenic acid content is 2.88%.
The preparation method comprises the following steps: decocting honeysuckle in 15 times of water for three times, each time for 0.5 hour, filtering decoction, combining filtrate, concentrating to 1/10 of the volume of original solution, stirring, adding 8 times of ethanol, standing, filtering, concentrating filtrate, recovering ethanol, adsorbing by using HPL-100 macroporous adsorption resin chromatographic column, eluting with 60% ethanol, collecting eluent, concentrating, recovering ethanol, adsorbing concentrate by using D-101 macroporous adsorption resin chromatographic column, sequentially carrying out gradient elution with 10%, 30% and 50% ethanol, collecting 50% eluent, concentrating, recovering ethanol, and spray-drying to obtain the honeysuckle extract, wherein chlorogenic acid content is 72.35-80.13 wt%.
Example eight preparation of honeysuckle extract of the invention
Medicinal materials: honeysuckle flower, chlorogenic acid content is 2.88%.
The preparation method comprises the following steps: decocting flos Lonicerae with 15 times of water for three times (0.5 hr each time), filtering, mixing filtrates, concentrating to 1/10 of the volume of the stock solution, stirring, adding 8 times of ethanol, standing, filtering, concentrating the filtrate, recovering ethanol, loading onto HPL-100 macroporous adsorbent resin chromatographic column for adsorption, eluting with 60% ethanol, collecting eluate, concentrating, recovering ethanol, loading onto D-101 macroporous adsorbent resin chromatographic column for adsorption, sequentially gradient eluting with 10%, 30% and 50% ethanol, collecting 50% eluate, concentrating, recovering ethanol, concentrating to obtain extract, adding ethyl acetate, heating for dissolving at 60deg.C, cooling to room temperature, crystallizing, filtering, and drying to obtain flos Lonicerae extract with chlorogenic acid content of more than or equal to 95wt%.
Example nine A process for preparing a powder for injection of the present invention
Prescription one
The preparation method comprises the following steps: weighing folium Eucommiae extract and glucose according to the prescription, dissolving in injectable water, filtering, spray drying, and packaging into 1000 bottles under aseptic condition.
Example ten the preparation method of the medicine powder injection of the invention
Prescription two
The preparation method comprises the following steps: weighing folium Eucommiae extract, glucose, and sodium chloride according to the prescription, dissolving in injectable water, filtering, spray drying, and packaging into 1000 bottles under aseptic condition.
Example eleven preparation of the powder for injection of the invention
Prescription III
The preparation method comprises the following steps: weighing folium Eucommiae extract and mannitol according to the prescription, dissolving in water for injection, filtering, spray drying, and packaging into 1000 bottles under aseptic condition.
EXAMPLE twelve preparation methods of the powder injection of the invention
Prescription IV
The preparation method comprises the following steps: weighing folium Eucommiae extract, aseptically packaging into 1000 bottles.
Example thirteen the preparation method of the powder injection of the medicine of the invention
Prescription five
The preparation method comprises the following steps: weighing folium Eucommiae extract, glucose, sodium bisulphite, dissolving in injectable water, filtering, and bottling to 1000 bottles.
Example fourteen preparation method of powder for injection of the invention
Prescription 6
The preparation method comprises the following steps: weighing folium Eucommiae extract and vitamin C according to the prescription, dissolving in water for injection, filtering, and bottling to 1000 bottles.
EXAMPLE fifteen seven methods for preparing the powder injection of the present invention
Prescription 7
The preparation method comprises the following steps: weighing flos Lonicerae extract, glucose, sodium bisulphite, dissolving in injectable water, filtering, and bottling to 1000 bottles.
The following experiments prove the beneficial effects of the invention.
Experimental example 1 test of efficacy of chlorogenic acid on canine parvovirus disease
1. Test materials
1.1 medicaments
Chlorogenic acid, content 99.2wt.%, was provided by Sichuan Jiu Chapter Biotechnology Co. Before use, the extract is dissolved in physiological saline to prepare about 15mg of chlorogenic acid in each 1 mL.
Physiological saline, available from Sichuan Korea pharmaceutical Co.
1.2 animals
12 Beagle dogs are used as male and female (female is not pregnant), and the age is 5-6 months, and the weight is 6.0-7.0 kg, which is provided by the laboratory animal institute of Sichuan province medical science institute canine farms.
1.3 Virus
Canine parvovirus, provided by the Qingdao animal and plant quarantine agency.
2. Test method
2.1 modeling
For healthy non-immunized dogs, the dogs are challenged with canine parvovirus virulent, and after 6 days, typical canine parvovirus clinical symptoms appear: the body temperature is raised to 40.1-41.0 ℃, mental depression, inappetence, vomiting, diarrhea, bloody stool and the like are detected by adopting a hemagglutination test and a hemagglutination inhibition test and a canine parvovirus rapid diagnosis test paper respectively, and the canine parvovirus disease is diagnosed.
2.2 animal administration
The Beagle dogs with canine parvovirus disease were randomly divided into 2 groups of 6, which are chlorogenic acid drug treatment group and negative control group respectively.
Chlorogenic acid medicine treatment group is injected with physiological saline solution of chlorogenic acid by 2mg/kg of muscle once daily for 10 days continuously; the negative control group was intramuscular injected with the same volume of physiological saline.
2.3 observation of clinical symptoms
The body temperature was measured 1 time a day in the morning and evening, and the dogs were observed for bowel movements, mental states, feeding and drinking and recorded. Clinical symptoms, disease progression and treatment efficacy of each group of diseased dogs were determined and compared. And analyzing the arrangement result, and counting the recovery and significant cases as effective cases to obtain the effective rate.
2.4 therapeutic efficacy criteria
(1) Clinical symptoms after healing: body temperature, spirit, appetite recovery, blood and stool stop, fecal formation, normal urination, etc.
(2) Clinical symptoms after the effective medication: body temperature, spirit and appetite are recovered to be normal, but feces are not formed or body temperature and spirit are recovered to be normal, but appetite is poor, feces are not formed and the like.
(3) The clinical symptoms are not improved or worsened and dead after the ineffective medication.
3. Test results
Table 1 clinical symptom observations at day 10 post-dosing
Note that: "/" indicates that death has occurred.
TABLE 2 effective efficacy of chlorogenic acid pharmaceutical treatment group
Compared with the negative control group, the Beagle dogs suffering from canine parvovirus disease have obviously improved body temperature, spirit, appetite and fecal state after intramuscular injection of chlorogenic acid solution.
In the Beagle dog treatment of the artificial infection pathogenic canine parvovirus disease, the treatment statistics of administering chlorogenic acid by intramuscular injection for 10 days are carried out, 4 animals are healed, 2 animals are obvious, no animal is dead, the cure rate is 67%, the obvious efficiency is 33%, the total effective rate is 100%, and the injection taking chlorogenic acid as the only active ingredient has good clinical application prospect for treating canine parvovirus disease.
Experimental example 2 test of efficacy of chlorogenic acid on canine distemper
1. Test materials
1.1 medicaments
Chlorogenic acid, content 99.2wt.%, was provided by Sichuan Jiu Chapter Biotechnology Co. Before use, the extract is dissolved in physiological saline to prepare about 15mg of chlorogenic acid in each 1 mL.
Physiological saline, supplied by Sichuan Korea pharmaceutical Co.
Canine quintuplet serum, provided by the military veterinary research institute at the military medical academy of sciences.
1.2 animals
36 dogs with confirmed diagnosis of canine distemper provided by Chengdu Huaxi pet hospital, male and female halves, age 1-2 years, weight 12-14 kg,
2. test method
2.1 modeling
36 diagnosed dogs were randomly divided into 3 groups of 12 each: the positive medicine group, the chlorogenic acid medicine treatment group and the negative control group observe and record the physiological index and clinical manifestation of the sick dogs.
2.2 animal administration
Dosing was performed according to experimental groups:
(1) Positive drug group: intramuscular injection of quintuplet serum, 1 ml/kg/time, once daily, for 15 days;
(2) Chlorogenic acid pharmaceutical group: intramuscular injection of chlorogenic acid in physiological saline solution at a dose of 2 mg/kg/time, once daily for 15 days;
(3) Negative control group: intramuscular injection of the same volume of physiological saline as group (2) was administered once daily for 15 days.
2.3 observation of clinical symptoms
The body temperature was measured 1 time a day in the morning and evening, and the dogs were observed for bowel movements, mental states, feeding and drinking and recorded. Clinical symptoms, disease progression and treatment efficacy of each group of diseased dogs were determined and compared. And analyzing the arrangement result, and counting the recovery and significant cases as effective cases to obtain the effective rate.
2.4 therapeutic efficacy criteria
(1) Clinical symptoms after healing: the temperature of the sick dogs is reduced to 38.5 ℃ or below, clinical symptoms such as listlessness, diarrhea and the like are not generated any more, and the appetite is recovered to be normal.
(2) Clinical symptoms after the effective medication: the body temperature, spirit, appetite and feces were normal with 2 or more.
(3) Clinical symptoms after ineffective administration: no improvement or worsening, and no death.
3. Test results
TABLE 3 observations of clinical symptoms at day 15 post-dose
Note that: "/" indicates that death has occurred.
Table 4 therapeutic effects of each administration group
Compared with the negative control group, the positive medicine and chlorogenic acid have obvious improvement on the body temperature, spirit, appetite and fecal state of dogs suffering from canine distemper.
From the above table, in the treatment of dogs suffering from canine distemper, the treatment of 15 days by intramuscular injection of positive drugs is carried out, 3 patients are healed, 4 patients are obvious, 5 patients are ineffective, the cure rate is 25%, the obvious efficiency is 33%, and the total effective rate is 58%; counting the treatment effect of chlorogenic acid for 15 days, wherein 7 patients are healed, 3 patients are effective, 2 patients are ineffective, the cure rate is 58%, the effective rate is 25%, and the total effective rate is 83%; the negative control group was not effective. Compared with a negative control group, the positive medicine and chlorogenic acid have obvious improvement on the body temperature, spirit, appetite and fecal state of dogs suffering from canine distemper; the injection taking chlorogenic acid as the only active ingredient has better treatment effect on canine distemper compared with the positive drug quintuplet serum, and has good clinical application prospect.
In summary, the invention provides the use of chlorogenic acid as the sole active ingredient in the preparation of a medicament or feed additive for preventing and/or treating canine parvovirus disease and canine distemper. Experimental results show that after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of puppies suffering from canine parvovirus disease are obviously improved, the cure rate of the medicine for canine parvovirus disease is 67%, the effective rate is 33%, and the total effective rate is 100%; after the medicine prepared by taking chlorogenic acid as the only active ingredient is applied, the body temperature, spirit, appetite and fecal state of a sick canine distemper are all obviously improved, the cure rate of the medicine for treating canine distemper is 58%, the effective rate is 25%, and the total effective rate is 83%. The chlorogenic acid has very outstanding effect of treating canine parvovirus disease and canine distemper, can treat canine parvovirus disease and canine distemper by single use, and has high effective rate. Chlorogenic acid as the only active ingredient has good application prospect in preparing medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper.
Claims (2)
1. Use of chlorogenic acid as sole active ingredient for the preparation of a medicament for the prevention and/or treatment of parvoviral and/or pestilence, characterized in that: the parvovirus disease is canine parvovirus disease, and the pestilence is canine distemper; the medicine is injection.
2. Use according to claim 1, characterized in that: the medicine contains chlorogenic acid 10mg-100mg per unit preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011192544.4A CN112293576B (en) | 2020-10-30 | 2020-10-30 | Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011192544.4A CN112293576B (en) | 2020-10-30 | 2020-10-30 | Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112293576A CN112293576A (en) | 2021-02-02 |
| CN112293576B true CN112293576B (en) | 2023-11-24 |
Family
ID=74332865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011192544.4A Active CN112293576B (en) | 2020-10-30 | 2020-10-30 | Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112293576B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512547A (en) * | 2011-12-14 | 2012-06-27 | 赵兴友 | Traditional Chinese medicine composition for treating canine distemper virus and preparation method thereof |
| CN104873634A (en) * | 2015-06-11 | 2015-09-02 | 刘洋 | Traditional Chinese medicine type dog food additive for preventing canine distemper of puppies as well as preparation method and use method thereof |
-
2020
- 2020-10-30 CN CN202011192544.4A patent/CN112293576B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512547A (en) * | 2011-12-14 | 2012-06-27 | 赵兴友 | Traditional Chinese medicine composition for treating canine distemper virus and preparation method thereof |
| CN104873634A (en) * | 2015-06-11 | 2015-09-02 | 刘洋 | Traditional Chinese medicine type dog food additive for preventing canine distemper of puppies as well as preparation method and use method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 异绿原酸在畜牧生产的应用前景;杨岸奇;李朝晖;张善文;;湖南饲料(04);49-51 * |
| 绿原酸的提取及其对猪细小病毒的体外作用研究;王学兵;魏战勇;崔保安;李长雷;徐端红;陈红英;;中国畜牧兽医(12);124-126 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112293576A (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028795B (en) | Chinese pulsatilla root granules for preventing and treating livestock and poultry bacterial diseases and preparation method and premix thereof | |
| CN114246878B (en) | Traditional Chinese medicine extract composition and preparation method and application thereof | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN110812474A (en) | Triple inactivated vaccine for porcine circovirus type 2, mycoplasma hyopneumoniae and haemophilus parasuis and preparation method thereof | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN112293576B (en) | Application of chlorogenic acid in preparation of medicines or feed additives for preventing and/or treating canine parvovirus diseases and canine distemper | |
| CN1943757A (en) | A Chinese traditional medicinal composition for treatment of hemicrania and its preparation method | |
| CN1269498C (en) | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method | |
| CN1273493C (en) | Angelica polysaccharide and its preparation and use | |
| CN1876045A (en) | A Chinese medicinal composition, its preparation process and quality control method | |
| CN1958008A (en) | Animal use compound medicament with effects of removing toxic heat, and preparation method | |
| CN102389496A (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN112656802B (en) | Application of pulsatilla saponin B4 in preparation of medicine for treating multiple sclerosis | |
| CN101423516A (en) | Preparation of pidotimod sodium and medicinal use thereof | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN103169825A (en) | Drug for treating enteric disease of beasts and birds | |
| CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN101073625A (en) | Medicinal composition with anti-infective and anti-inflammatory functions | |
| CN1494902A (en) | Application of high-solubility berberine in preparation of medicine. | |
| CN101926846A (en) | Medicinal composition for treating pullorum disease and preparation method thereof | |
| AU2021105905A4 (en) | A Pharmaceutical Composition for Treating Diarrhea Of Piglet And Its Preparation Method | |
| CN116036188B (en) | Traditional Chinese medicine composition for preventing and treating chicken coccidiosis as well as preparation method and application thereof | |
| CN113827603B (en) | Application of adefovir in preparing medicine for treating glioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |